Nonalcoholic fatty liver disease in asymptomatic obese women

Annals of Hepatology

Volumn 9, Issue 2, 2010, Pages 144-149

  Rodriguez Hernandez, Heriberto ^a,b,c   Cervantes Huerta, Miriam ^a   Gonzalez, Jose Luis ^a   Marquez Ramirez, Maria Dolores ^a   Rodriguez Moran, Martha ^a,b   Guerrero Romero, Fernando ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Research Group on Diabetes and Chronic Illnesses   (Mexico)

^c UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

Diabetes; Nafld; Nash; Obesity; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY MASS; DISEASE COURSE; EARLY DIAGNOSIS; ENZYME ASSAY; FATTY LIVER; HYPERGLYCEMIA; METABOLISM; MEXICO; MIDDLE AGED; NEEDLE BIOPSY; PREDICTION AND FORECASTING; RISK FACTOR; SEX DIFFERENCE;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; BLOOD GLUCOSE; BODY MASS INDEX; CLINICAL ENZYME TESTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DISEASE PROGRESSION; EARLY DIAGNOSIS; FATTY LIVER; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIVER CIRRHOSIS; MEXICO; MIDDLE AGED; OBESITY; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 77956646298     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31652-7     Document Type: Article

References (31)

1. Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: An overview. J Gastroenterol Hepatol 2002; 17: 1136-43.
2. Hamer OW, Aguirre D, Casola G, Sirlin CV. Imaging features of perivascular fatty infiltration of the liver. Radiology 2005; 237: 159-69.
3. Adams LA, Lymp JF, Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005; 129: 113-21.
4. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
5. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8: S4-S8.
6. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1518-23.
7. Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu YC, Mc-Cullough A. Nonalcoholic fatty liver disease: A spectrum of clinical and pathologic severity. Gastroenterology 1999; 116: 1413-9.
8. Charatcharoenwitthaya P. Lindor K. Role of radiologic modalities in the management of non-alcoholic steatohepati-tis. Clin Liv Dis 2007; 11: 37-54.
9. Saadeh S, Younossi Z, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 750-4.
10. Abdelmalek MF, Diehl AM. Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin N Am 2007; 91: 1125-49.
11. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-33.
12. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
13. Olaiz G, Rojas R, Barquera S, Shamah T, Aguilar C, Cravioto P, Lopez P, Hernandez M, Tapia R, Sepulveda J. Encuesta Nacional de Salud 2000. Tomo 2. La salud de los adultos. Cuernavaca, Morelos, Mexico. Institute Nacional de Salud Publica, 2003.
14. Nakao K, Nakata K, Ohtsubo N, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002; 97: 1796-801.
15. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708-15.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Te-tri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
17. American Diabetes Association. Diagnosis and Classification of diabetes mellitus. Diabetes Care 2005; 28 (Suppl 1): S37-S42.
18. Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-97.
19. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-7.
20. Prati D, Taioli E, Zanella A, Delia Torre E, Butelli S, Del Vec-chio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
21. Kramer MS (ed). Clinical Epidemiology and Biostatistics. A Primer for investigators and Decision-Makers. Berlin: Springer-Verlag Press, 1988: 201-210.
22. Ruhl CE, Evaerhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003; 124: 71-9.
23. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Et Metabolism 2008; 34: 634-7.
24. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.
25. Bedogni G, Miglioli L, Masutti F, et al. incidence of natural course of fatty liver in the general population: The dyoni-sos study. Hepatology 2007; 46: 1387-91.
26. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8: S4-S8.
27. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-95.
28. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16:421-7.
29. Paradis V, Bedossa P. Definition and natural history of metabolic steatosis: histology and cellular aspects. Diabetes Et Metabolism 2008; 34: 638-42.
30. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007; 102: 399-408.
31. Argo CK, Northup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51: 371-9.